Inventor · disambiguated record
Fabrice Le Gall
Also filed as: LE GALL FABRICE
8 granted patents·14 pending applications·121 citations·filing 2002–2023
87Inventor score
Files withBIONTECH AG5AFFIMED GMBH3AFFIMED THERAPEUTICS AG3LITTLE MELVYN3GANYMED PHARMACEUTICALS GMBH2
Top patents by PatentIndex Score
22 records- 0192US9226962B2Human CD3-specific antibody with immunosuppressive propertiesAFFIMED THERAPEUTICS AG·Filed 2013·Granted Jan 5, 2016·38 cites·6 claims
- 0292US9035026B2Anti-CD16 binding moleculesHOFFMANN KARIN·Filed 2006·Granted May 19, 2015·54 cites·21 claims
- 0390US10717780B2Agents for treatment of claudin expressing cancer diseasesBIONTECH AG·Filed 2018·Granted Jul 21, 2020·5 cites·12 claims
- 0489US9701750B2Anti-CD16 binding moleculesAFFIMED GMBH·Filed 2015·Granted Jul 11, 2017·11 cites·16 claims
- 0585US11787862B2Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseasesBIONTECH AG·Filed 2017·Granted Oct 17, 2023·3 cites·32 claims
- 0684US10093736B2Agents for treatment of claudin expressing cancer diseasesBIONTECH AG·Filed 2013·Granted Oct 9, 2018·7 cites·9 claims
- 0780US11541127B2Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 3, 2023·2 cites·28 claims
- 0874US2024228616A1Agents for Treatment of Claudin Expressing Cancer DiseasesBIONTECH AG·Filed 2022·Application pending·0 cites
- 0970US2023270878A1Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 1070US2024158501A1Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseasesBioNTech SE·Filed 2023·Application pending·0 cites
- 1169US7901677B1Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer typesAFFIMED THERAPEUTICS AG·Filed 2006·Granted Mar 8, 2011·1 cites·13 claims
- 1265US2020399370A1Agents for Treatment of Claudin Expressing Cancer DiseasesBIONTECH AG·Filed 2020·Application pending·0 cites
- 1363US2018346590A1Antigen-binding molecule and uses thereofAffimed GmbBH·Filed 2018·Application pending·0 cites
- 1456US2015225484A1Antigen-binding molecule and uses thereofAFFIMED GMBH·Filed 2015·Application pending·0 cites
- 1556US2022048994A1Trifunctional antigen-binding moleculeLITTLE MELVYN·Filed 2021·Application pending·0 cites
- 1656US2013189263A1Antigen-binding molecule and uses thereofLITTLE MELVYN·Filed 2012·Application pending·0 cites
- 1756US2008145362A1Antibody combination useful for tumor therapyAFFIMED THERAPEUTICS AG·Filed 2008·Application pending·0 cites
- 1853US2006233787A1Human cd3-specific antibody with immunosuppressive propertiesLE GALL FABRICE·Filed 2003·Application pending·0 cites
- 1951US2011206672A1Antigen-Binding Molecule And Uses ThereofLITTLE MELVYN·Filed 2011·Application pending·0 cites
- 2047US2005079170A1Dimeric and multimeric antigen binding structureFiled 2002·Application pending·0 cites
- 2147US2005176934A1Antibody combination useful for tumor therapyFiled 2003·Application pending·0 cites
- 2242US2017037128A1Trifunctional antigen-binding moleculeAFFIMED GMBH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Fabrice Le Gall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →